Molecular Docking, Synthesis, and, Biological Activity of New Diclofenac Derivatives Incorporating 1,2,4-Triazole Ring as a Promising Antibacterial Agents
DOI:
https://doi.org/10.31351/vol34iss1pp165-175Keywords:
Diclofenac, Molecular Docking, 1,2,4-triazole, antibacterial activity, benzoyl chloride derivativesAbstract
NSAIDs, recently have been shown to exert a wide variety of biological activities, such as antibacterial, antifungal, antioxidant, and anticancer activity. The triazole ring has various pharmacological activities of tetrazole ring, anticancer, antidiabetic, antifungal, antioxidant, anticonvulsant, antiviral, and antibacterial properties. Hence, the aim of this study was to design, synthesize, molecular docking, and assess the antibacterial activity of new diclofenac derivatives incorporating a 1,2,4-triazole ring. Molecular docking studies were carried out using MOE 2015 software using a standard protocol. The new diclofenac derivatives (VIa-d) were synthesized by esterifying diclofenac, reacting the product with hydrated hydrazine and carbon disulfide, and cyclization to form a 1,2,4-triazole ring. Finally, the reaction of the benzoyl chloride derivatives with the primary amino group on the synthesized triazole ring via a nucleophilic substitution reaction. In vitro antibacterial activity of diclofenac, and the synthesized compounds were evaluated by using the agar-well diffusion method. Compounds (VIa-d) have shown a higher binding score than the reference ligand (Topotecan) against Human DNA topoisomerase I (PDB: 1K4T), while they were nearly identical to the reference ligand (levofloxacin) against type IV topoisomerase from S. pneumoniae (PDB: 3RAE). All of the compounds inhibited growth of the Staphylococcus aureus and Escherichia coli, with compound VId exhibiting the highest level of activity.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatol. 2021;3(7):e498–506.
Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143–50.
Edinoff AN, Houk GM, Patil S, Siddaiah HB, Kaye AJ, Iyengar PS, et al. Adjuvant drugs for peripheral nerve blocks: The role of alpha-2 agonists, dexamethasone, midazolam, and non-steroidal anti-inflammatory drugs. Anesth Pain Med. 2021;11(3).
Shneine J. Synthesis, characterization, and antibacterial activity of new schiff’s bases with 1, 2, 4-triazole moiety. 2017;(January 2015).
Hamadameen BM, Ameen DMH. Synthesis, Characterization, and Antibacterial Activity of Novel Mutual Non-Steroidal Anti-inflammatory Prodrugs. Zanco J Pure Appl Sci. 2019;31(6).
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
Yadav AR, Mohite SK. Cancer-A silent killer: An overview. Asian Journal of Pharmaceutical Research. 2020;10(3):213.
Reynolds BA, Oli MW, Oli MK. Eco-oncology: Applying ecological principles to understand and manage cancer. Ecol Evol. 2020;10(16):8538–53.
Bonev BB, Brown NM. Bacterial resistance to antibiotics - from molecules to man. Bacterial Resistance to Antibiotics: From Molecules to Man. 2019. 1–239 p.
Derry S, Wiffen PJ, Moore RA. Single dose oral diclofenac for acute postoperative pain in adults. Cochrane Database of Systematic Reviews. 2015;2017(10).
Dutta NK, Mazumdar K, Park JH. In vitro synergistic effect of gentamicin with the anti-inflammatory agent diclofenac against Listeria monocytogenes. Lett Appl Microbiol. 2009;48(6):783–5.
Zhang S, Qu X, Tang H, Wang Y, Yang H, Yuan W, et al. Diclofenac Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactams and Prevents Implant Infections. Advanced Science. 2021;8(13):1–16.
Kaur R, Ranjan Dwivedi A, Kumar B, Kumar V. Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review. Anticancer Agents Med Chem. 2015;16(4):465–89.
Mareddy J, Suresh N, Kumar CG, Kapavarapu R, Jayasree A, Pal S. 1,2,3-Triazole-nimesulide hybrid: Their design, synthesis and evaluation as potential anticancer agents. Bioorg Med Chem Lett. 2017;27(3):518–23.
Bayrak H, Demirbas A. Synthesis of some new 1 , 2 , 4-triazoles , their Mannich and Schiff bases and evaluation of their antimicrobial activities. 2009;44.
Mohammad A, Sharma S, Bhawani SA. Reversed phase thin layer chromatography of five co-administered drugs with surfactant modified solvent systems. Indian Journal of Chemical Technology. 2009;16(4):344–50.
S. A. Hasan and A. N. Elias, “Synthesis of new diclofenac derivatives by coupling with chalcone derivatives as possible mutual prodrugs,” Int. J. Pharm. Pharm. Sci., vol. 6, no. 1, pp. 239–245, 2014.
N. H. Naser, M. F. Mahdi, T. N-A Omar, and A. A. Fadhil, “Synthesis and Preliminary Pharmacological Evaluation of New Analogues of Diclofenac as Potential Anti-inflammatory Agents,” Iraqi J. Pharm. Sci. ( P-ISSN 1683 - 3597 , E-ISSN 2521 - 3512), vol. 20, no. 1, pp. 25–32, 2017, doi: 10.31351/vol20iss1pp25-32.
J. B. Christensen, “A simple method for synthesis of active esters of isonicotinic and picolinic acids,” Molecules, vol. 6, no. 1, pp. 47–51, 2001, doi: 10.3390/60100047.
N. A. Alsaif, M. A. Bhat, M. A. Al-omar, H. M. Al-tuwajiri, A. M. Naglah, and A. Al-dhfyan, “Synthesis of Novel Diclofenac Hydrazones : Molecular Docking , Anti-Inflammatory , Analgesic , and Ulcerogenic Activity,” vol. 2020, 2020.
V. Sumangala, B. Poojary, N. Chidananda, T. Arulmoli, and S. Shenoy, “Synthesis and biological evaluation of some Schiff bases of 4-amino-5-(4-methylsulfonyl)benzyl-2,4-dihydro-3H-[1,2,4]-triazole-3-thione,” Med. Chem. Res., vol. 22, no. 6, pp. 2921–2928, 2013, doi: 10.1007/s00044-012-0294-5.
A. Husain, M. a Naseer, and M. Sarafroz, “Drug Synthesis Synthesis and Anticonvulsant Activity of Some Novel Fused,” Acta Pol. Pharm., vol. 66, no. 2, pp. 135–140, 2009.
B. Sejdiu and D. P. Tieleman, “COX-1 – lipid interactions: arachidonic acid, cholesterol, and phospholipid binding to the membrane binding domain of COX-1,” pp. 1–29, 2020.
M. Saeedi et al., “Synthesis and biological investigation of some novel sulfonamide and amide derivatives containing coumarin moieties,” Iran. J. Pharm. Res., vol. 13, no. 3, pp. 881–892, 2014.
Attique SA, Hassan M, Usman M, Atif RM, Mahboob S, Al-Ghanim KA, et al. A molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension. Int J Environ Res Public Health. 2019;16(6):1–17.
Egieyeh S, Egieyeh E, Malan S, Christofells A, Fielding B. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2). PLoS One. 2021;16(1):1–14.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
